ArticleAmerican journal of ophthalmology case reports2022
Rho-Associated Kinase Inhibitor Eye Drops in challenging cataract surgery.
Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.Eye (London, England) · 2024Pooled it
- Rho-Kinase Inhibitor-A Molecule for Pharmacological Treatment of Decompensated Corneas: Case Series.Biomedicines · 2026Article
- RhoKinase (ROCK) Inhibition as a Therapeutic Strategy for Pseudophakic Bullous Keratopathy: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Clinical Evaluation of Ripasudil for Corneal Edema: A Large-Scale Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Therapeutic Potential of Rho Kinase Inhibitors in Corneal Disease: A Systematic Review of Preclinical and Clinical Studies.Biomedicines · 2025Review
- Rho-Kinase Inhibitors in the Management of Fuchs Endothelial Corneal Dystrophy: A Review.Medicina (Kaunas, Lithuania) · 2025Review
- Rho Kinase Inhibitors in Glaucoma Management: Current Perspectives and Future Directions.Drug design, development and therapy · 2025Review
- The Role of Rho Kinase Inhibitors in Corneal Diseases.Drug design, development and therapy · 2024Review
- Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment.Ophthalmology and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the impact of Rho-Associated Kinase Inhibitor Eye Drops in cases of cataract surgery performed in severe Fuchs' endothelial corneal dystrophy (FECD). OBSERVATIONS: A patient affected by FECD stage II underwent femtosecond laser-assisted cataract surgery (FLACS), developed postsurgical corneal failure and was scheduled for endothelial keratoplasty. Compassionate treatment with Rho-Associated Kinase Inhibitor Eye Drops 4 times per day was started. A significant improvement in visual acuity and corneal failure was recorded. Thereafter, other two patients affected by FECD stage II were prophylactically treated with Rho-Associated Kinase Inhibitor Eye Drops 4 times per day for three months before FLACS with good visual and clinical outcome. CONCLUSIONS AND IMPORTANCE: These cases expand upon the reported effects of rho-associated kinase inhibitor Ripasudil in the FECD, suggesting a role as adjuvant medical therapy in patients advised for intraocular surgery to improve endothelial function and reduce the risk of pseudophakic bullous keratopathy (PBK).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.